BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30953185)

  • 21. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
    Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
    Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
    J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia.
    Inoue O; Hamatani T; Susumu N; Yamagami W; Ogawa S; Takemoto T; Hirasawa A; Banno K; Kuji N; Tanaka M; Aoki D
    Reprod Biol Endocrinol; 2016 Jan; 14():2. PubMed ID: 26769300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Fertility-sparing management of endometrial cancer and atypical hyperplasia].
    Gonthier C; Trefoux-Bourdet A; Luton D; Koskas M
    Gynecol Obstet Fertil Senol; 2017 Feb; 45(2):112-118. PubMed ID: 28368791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.
    Pronin SM; Novikova OV; Andreeva JY; Novikova EG
    Int J Gynecol Cancer; 2015 Jul; 25(6):1010-4. PubMed ID: 25950126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer.
    Falcone F; Laurelli G; Losito S; Di Napoli M; Granata V; Greggi S
    J Gynecol Oncol; 2017 Jan; 28(1):e2. PubMed ID: 27670256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
    Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
    Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Classification in Patients With Endometrial Cancer After Fertility-Preserving Treatment: Application of ProMisE Classifier and Combination of Prognostic Evidence.
    Ran X; Hu T; Li Z
    Front Oncol; 2022; 12():810631. PubMed ID: 35664732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis.
    Fan Z; Li H; Hu R; Liu Y; Liu X; Gu L
    Int J Gynecol Cancer; 2018 Feb; 28(2):385-393. PubMed ID: 29266019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer.
    Chae SH; Shim SH; Lee SJ; Lee JY; Kim SN; Kang SB
    Int J Gynecol Cancer; 2019 Jan; 29(1):77-85. PubMed ID: 30640687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
    Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
    Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
    Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
    Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical efficacy and pregnancy outcomes of fertility-preserving re-treatment after recurrence of the patient with atypical endometrial hyperplasia and early stage endometrial carcinoma].
    He YJ; Wang YQ; Tang HR; He M; Rao Y; Zhou R; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2020 Jan; 55(1):21-28. PubMed ID: 32074769
    [No Abstract]   [Full Text] [Related]  

  • 35. Diagnostic utility of phosphatase and tensin homolog, beta-catenin, and p53 for endometrial carcinoma by thin-layer endometrial preparations.
    Norimatsu Y; Miyamoto M; Kobayashi TK; Moriya T; Shimizu K; Yanoh K; Tsukayama C; Miyake Y; Ohno E
    Cancer; 2008 Jun; 114(3):155-64. PubMed ID: 18431720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SPECIFICITIES OF ENDOMETRIAL PROLIFERATION/STEM CELL INDEX DISTRIBUTION IN ENDOMETRIOID CARCINOMA OF DIFFERENT GRADE OF MALIGNANCY.
    Kikalishvili N; Beriashvili R; Muzashvili T; Burkadze G
    Georgian Med News; 2018 Mar; (276):117-123. PubMed ID: 29697394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer.
    Park JY; Seong SJ; Kim TJ; Kim JW; Bae DS; Nam JH
    Gynecol Oncol; 2017 Jul; 146(1):39-43. PubMed ID: 28526167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bariatric Surgery: Does It Play a Role in Fertility-Preserving Treatment Among Obese Young Women With Endometrial Cancer?
    Benito V; López-Tomassetti E; Esparza M; Arencibia O; Andújar M; Prieto M; Lubrano A
    J Minim Invasive Gynecol; 2015; 22(5):906-9. PubMed ID: 25843520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
    PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
    Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D
    Am J Obstet Gynecol; 2014 Mar; 210(3):255.e1-4. PubMed ID: 24211482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.